Mini-Sentinel Safety Review Of Xarelto Expands FDA’s Scrutiny Of Anticoagulants
This article was originally published in The Pink Sheet Daily
Executive Summary
The postmarket safety assessment of J&J/Bayer’s Xarelto will use Mini-Sentinel’s Prospective Routine Observational Monitoring Programming Tools surveillance system, a new program that can track new drugs as they enter the market on an ongoing, semi-automated basis.